Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This
requires not only that cancer-specific T cells be generated, but also that these T cells …

The signaling mechanisms between prostate cancer cells and infiltrating immune cells may
illuminate novel therapeutic approaches. Here, utilizing a prostate adenocarcinoma model …

Inflammation is a hallmark of cancer. In patients with cancer, peripheral blood myeloid
expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter …

Prostate cancer is a major cause of cancer morbidity and mortality. Intra-prostatic
inflammation is a risk factor for prostate carcinogenesis, with diet, chemical injury and an …

Immune evasion is a hallmark of cancer, enabling tumors to survive contact with the host
immune system and evade the cycle of immune recognition and destruction. Here, we …

Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent
developments in cancer immunotherapy have had significant clinical impact, only a subset …

Combining immune checkpoint therapy (ICT) and targeted therapy holds great promises for
broad and long-lasting anti-cancer therapies. However, combining ICT with anti-PI3K …